References
MIRD. MIRD primer for absorbed dose calculations. The Society of Nuclear Medicine, New York, 1988.
Izembart M., Chavaudra J., Aubert B., Vallée G. Retrospective evaluation of the dose received by the ovary after radioactive iodine therapy for thyroid cancer. Eur. J. Nucl. Med. 19: 243, 1992.
Schull W.J., Otake M., Neel J.V. Genetic effects of atomic bombs: a reappraisal. Science 213: 1220, 1981.
Otake M., Schull W.J., Nell J.V. Congenital malfomations, stillbirths, and early mortality among the children of atomic bomb survivors: a renalysis. Radiat. Res. 122: 1, 1990.
Yoshimoto Y., Neel J.V., Schull W.J., et al. Malignant tumors during the first 2 decades of life in the offspring of atomic bomb survivors. Am. J. Hum. Genet. 46: 1041, 1990.
Mulvihill J.J., Myers M.H., Connely R.R., et al. Cancer in offspring of long-term survivors of chilhood and adolescent cancer. Lancet ii: 813, 1987.
Hawkins M.M., Draper G.J., Smith R.A. Cancer among 1348 offspring of survivors of childhood cancer. Int. J. Cancer 43: 975, 1989.
Hawkins M.M. Is there evidence of a therapy related increase in germ cell mutation among childhood cancer survivors? J. Natl. Cancer. Inst. 83: 1643, 1991.
Sever L.E., Gilbert E.S., Hessol N.A., McIntyre J.M. A case-control study of congenital malfomations and occupational exposure to low-level ionizing radiation. Am J. Epidemiol. 127: 226, 1988.
Gardner M.J., Snee M.P., Hall A.J., et al. Results of a case-control study of leukemia and lymphoma amongw young people near Sellafield nuclear plant in West Cumbria. Br. Med. J. 300: 423, 1990.
Hayek A., Chapman E.M., Crawford J.D. Long-term results of treatment of thyrotoxicosis in children and adolescents with radioactive iodine. New Engl. J. Med. 283: 949, 1970.
Safa A.M., Schumacher O.P., Rodriguez-Antunez A. Long-term follow-up results in children and adolescent treated with radioactive iodine (I-131) for hyperthyroidism. New Engl. J. Med. 292: 167, 1975.
Freitas J.E., Swanson D.P., Gross M.D., Sisson J.C. lodine-131: optimal therapy for hyperthyroidism in children and adolescents? J. Nucl. Med. 1979; 20: 847–50.
Winship T., Rosvoll R.V. Thyroid carcinoma in chilhood. Final report on a 20 year study. Proc. Natl. Cancer Conf. 6: 677, 1970.
Einhorn J., Hulten M., Lindsten J., Wickhund H., Zetterquivist P. Clinical and cytogenetic investigation in children of parents treated with radioiodine. Acta Radiol. 11: 193, 1972.
Sarkar S.D., Beiewaltes W.H., Gill S.P., Cowley B.J. Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J. Nucl. Med. 17: 460, 1976.
Edmonds C.J., Smith T. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br. J. Radiol. 59:45, 1986.
Enrich D., Creutzig H. Benefits and risks of radioactive iodine therapy in differentied thyroid carcinoma. Prog. Surg, Basel: Karger, 19: 133, 1988.
Casara D., Rubello D., Saladini G, et al. Pregnancy after high therapeutic doses of iodine-131 in differentied thyroid cancer: potential risks and recommendations. Eur. J. Nucl. Med. 20: 192, 1993.